Member Info for Newuncle

Movin up nicely......fingers xxxd

+60% 🚀🚀🚀

I saw SCE raise at a huge discount from 2p to 1p recently was able to buy loads sub 1p, then roseand rose and rose smashed back through 2p like a knife through butter. Also on CSFS who did a massive discounted fund raise at just 6p, hit 40p within 12 months.

Clearly OBD can't fund itself in the near term via sales, so it's all about spending cash raised to keep the business alive, pretty shocking really. Burn rate is frightening and means another cash raise will be needed before year end imo

🎈🎈🎈🎈🎈

You mean Mr 2% buyer today?

🔥🌊🌊🌊

Being taken at 0.00125

Plenty of buyers at 0.0012 showing now

+50% 🚀

Moving up again 🚀

Early May coverage note fwiw:

Positive trading update CAP-XX has announced that current trading on existing products remains strong, in line with management forecasts, and trial shipments of pre-samples of new product have recently commenced. Bookings and billings are 14% and 56% ahead respectively for the financial year to date compared with the comparative period in 2023, along with a current book to bill ratio of 1.12. The order backlog remains close to US$1m. - Investments are being made for growth, including the continued expansion of the sales representative and distribution network, and working capital for the market introduction of the new DMH and SMD products. An initial pre-series batch of fully functional DMH product is currently under lab evaluation and SMD testing remains on track. We see the launch of new unique products such as the DMH this year and SMD in FY25E as key drivers for higher-margin revenue growth in the coming years. - Legal costs effectively over. After agreeing settlements with Maxwell/Tesla and AVX, and – apart from the final settlement of legal costs associated with the Maxwell/Tesla litigation, which CAPXX does not consider material – the only remaining payments for legal costs will be normal ongoing corporate legal expenses such as those associated with applications for patents. - FY25E to benefit from cost-reduction programme, which the company believes has delivered annualised operating cost savings of more than US$0.5m (cA$0.75m). The company will be providing a more detailed update on the business with a capital markets seminar after the year end, which will enable us to provide a more complete analysis of this. - Target for breakeven in the 2026 calendar year, which aligns with our forecasts. Whilst the trading update is positive, there are no comparative figures to which to compare the 56% growth rate, although this growth rate compares favourably to the performance from peers in the supercapacitor space and the wider passive electronic components sector, which continues to be affected by the geopolitical macro backdrop. This trading update does, however, show that the company is back on a growth track, and – with a lower cost base and strengthened balance sheet post fund raise to invest in product launches and growth – that the company looks to be turning around under the new CEO’s updated strategy. We look forward to more financial detail to be released post year-end in the proposed capital markets seminar to provide a more detailed analysis of the trading and update our forecasts. In the meantime, we note that we believe the current valuation does not reflect the IPO position, current trading and prospects for the company.

Broker Coverage today:

Financial performance muted for now: OBD is still relatively early in implementing its plans to maximise the commercial potential of the EpiSwitch platform and we believe that efforts have been highly creditable given current resources. Revenues of £0.33m remain modest although we note that revenues continue to lag sales particularly with CiRT, where the majority of sales are reimbursed by US insurers. Growing sales of PSE should help redress the balance given that 19% of orders are currently cash based and the expectation is that this will increase. For the future, the sheer size and opportunity of the PSE test once successfully commercialised is the key to supporting future financial independence of the company and the company achieves its 1000 tests per month objective. Inevitably, the increased activity generally with increased lab space and additional (more experienced) sales hires as OBD seeks to optimise its commercial business model has led to increased costs and an operating loss of £6.0m. We note that the company bolstered its cash resources by raising £9.9m gross in March 2024 and we look forward to the potential for the company to secure partners for the canine cancer (EpiSwitch SCB) and colorectal cancer (EpiSwitch NST) programmes which could boost cash resources. House Stock

From ADVFN poster - Discuss

This just doesnt stack as a future viable business, 53 staff in situ paid £2.978m gross ie an average annualised salary of £112,000 & £6m pa in total (R&D is extra!), plus annualised normal admin costs excluding exceptionals £4.4m ie £10m+

12,000 pse target @ £750 ie £9m sales @ 40% margin taken from those accounts ie £3.6m gross profit before admin costs. Add CiRT fwiw.

This can only end with a bigger biotech picking up the IP & shareholders shafted

Zak Mir covered it today, big target from him fwiw

MajorH,

Do you know of such a wally?

This share is troooooley bonkers......but fun

Oh no you wouldn't have, not at the prices they want for something which remains unvalidated by any national health bodies.

Burrows is so stoopid it's not funny any more.

Validate your tests, then sell them. Not the other way around because it just won't happen

There you go Roger, Myles has pretty much printed a carbon copy of my posts I have been making here for ages which you trashed daily. Go on then, say something funny now Roger you utter 4hit of a man.

Morning MG - have been watching CAP-XX for a long while (didn't take the recent placing, but was intrigued).

Decided to take a chunk of #CPX today (~2.3%), following those three NED appointments.

Combined with the:

- recently strengthened balance sheet;

- the clearing of all litigation;

- the ongoing cost reduction programme;

- bookings/billings being nicely ahead in 2024 (relative to 2023);

- further patents incoming;

I thin the company is now properly in turnaround mode. Sub £3m mkt cap. Quite obvious (to me, anyway!) that this could run hard in the coming weeks.